Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages
By S. Gillen, T. Schuster, C. Meyer zum Büschenfelde, H. Friess, J. Kleeff. PLoS Medicine, 2010
1,527 citations recorded by the source corpus.
Jörg Kleef and colleagues systematically reviewed studies on neoadjuvant therapy and tumor response, toxicity, resection, and survival percentages in pancreatic cancer and suggest that patients with locally nonresectable tumors should be included in neoadjuvant protocols.
View Paper: https://www.semanticscholar.org/paper/f5dcec2dc41f8316f3d157bc7df5295ae747ec67
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
Citations in the corpus
- Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial (2018, background): “However, the role of aggressive surgical treatment is questionable because of the high morbidity, low R0 resection, and high early systemic recurrence.(2,4) A neoadjuvant approach for the treatment of BRPC or unresectable pancreatic cancer has many theoretical advantages, including early systemic tr”
- Recent progress in pancreatic cancer (2013, background): “It does have the advantage of downstaging some locally advanced patients and sterilizing the margin of borderline resectable patients allowing them to undergo a surgery with a higher likelihood of an R0 resection.(114,120) In fact, 15% to 40% of patients with initially borderline or unresectable tum”
- Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2015, result): “Small retrospective studies and two meta-analyses, including patients with both borderline and resectable lesions, have reported an even better survival for these patients than for those with immediately resectable tumours [32, 33].”